Amplitude Ventures, a capital catalyst for highly innovative companies, and Fonds de solidarité FTQ, an investment firm, led a $50m Series A round in Congruence Therapeutics, a biotechnology company, with participation from Lumira Ventures, Investissement Quebec, OrbiMed Advisors, and Driehaus Capital Management. "Our industry faces a watershed moment where the application of novel computational tools, including machine learning, is poised to disrupt traditional drug discovery. Our proprietary computational platform, Revenir™, has already demonstrated its ability to uncover novel biophysical features of certain proteins that underpin disease. This financing will allow us to build out a world-class team of 'drug hunters' to efficiently design novel small molecules for rare diseases of high unmet medical need, and progress them toward and into the clinic. We are grateful for the strong commitment provided by our syndicate of investors," Dr Clarissa Desjardins, Congruence Therapeutics Founder.